{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:04Z","timestamp":1761016924097,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.eplepsyres.2011.09.019","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T06:07:19Z","timestamp":1319609239000},"page":"269-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Changed constitution without change in brand name \u2013 The risk of generics in epilepsy"],"prefix":"10.1016","volume":"98","author":[{"given":"Vishal","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J.","family":"Cordato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy G.","family":"Beran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","article-title":"Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes","volume":"48","author":"Andermann","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0010","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1528-1157.1999.tb00841.x","article-title":"Lamotrigine and valproate, pharmacodynamic interaction","volume":"40","author":"Beran","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy. Case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2005.12.010","article-title":"Are there potential problems with generic substitution of antiepileptic drugs? A review of issues","volume":"15","author":"Crawford","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0025","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000123693.82339.FC","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0030","unstructured":"Generic Pharmaceutical Association, 2011. Facts at a glance. www.gphaonline.org\/about-gpha\/about-generics\/facts."},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0035","unstructured":"GlaxoSmithKline (Product Information), 2010. Lamictal (lamotrigine) tablets (Lamictal (lamotrigine) chewable dispersible tablets. Lamictal ODT (lamotrigine) orally disintegrating tablets. http:\/\/us.gsk.com\/products\/assets\/us_lamictal.pdf."},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0040","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/ph3082470","article-title":"Use of generics\u2014a critical cost containment measure for all healthcare professionals in Europe","volume":"3","author":"Godman","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.yebeh.2010.05.015","article-title":"Economic burden associated with the use of generic antiepileptic drugs in the United States","volume":"18","author":"Helmers","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0055","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective study following the introduction of a routine service","volume":"46","author":"Morris","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1017\/S1092852900027358","article-title":"Understanding therapeutic equivalence in epilepsy","volume":"15","author":"Sankar","year":"2010","journal-title":"CNS Spectr."},{"key":"10.1016\/j.eplepsyres.2011.09.019_bib0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.seizure.2007.11.023","article-title":"Lamotrigine therapeutic thresholds","volume":"17","author":"S\u00f8ndergaard Khinchi","year":"2008","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111100283X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111100283X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:27:17Z","timestamp":1760275637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012111100283X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":15,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S092012111100283X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.09.019","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changed constitution without change in brand name \u2013 The risk of generics in epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}